AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00004146 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiotherapy
Study NCT00004146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboxyamidotriazole
Description: Given orally
Study NCT00004146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT02165410 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ASL-MRI
Description: ASL MRI is a non-invasive technique without injection to measure rCBF at rest marking the intravascular water molecules and use it as an endogenous tracer. Premedication, if required, will concern autistic and mentally retarded subjects only.
Study NCT02165410 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diffusion tensor imaging (diffusion MRI)
Description: Diffusion MRI enables the mapping of the diffusion process of water molecules, which allows visualizing anatomical connections between different parts of the brain, noninvasively and on an individual basis. The sequence is acquired following clinical MRI sequences, while the child is still inside the MRI machine, with no further intervention applied.
Study NCT02324699 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vedolizumab
Description: 300mg IV over 30 minutes. Both arms will receive vedolizumab at weeks 0, 2, and 6.
Study NCT02324699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: 300mg IV over 30 minutes. Both arms will receive vedolizumab at weeks 0, 2, and 6.
Study NCT02165410 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resting state MRI
Description: This sequence is based on the synchronization of fluctuations in the blood-oxygen level dependent (BOLD) signal of different brain regions that work as a network. Therefore this sequence allows for the establishing of maps of funcitonal connectivity.
Study NCT02165410 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Eye-tracking
Description: Eye tracking is a non-invasive method that allows objectifying gaze parameters during presentation of stimuli on a computer screen. Children will be presented with a series of social and no social stimuli and are required to watch it, with no further intervention applied.
Study NCT02165410 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive profile
Description: Children will be asked to perform certain tasks, adapted for their age.
Study NCT03234361 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Phosphate Phase
Description: 2 capsules of sodium phosphate with 500mg/day of phosphate.
Study NCT03234361 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low Phosphate Phase
Description: 2 capsules of sodium chloride.
Study NCT03253120 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Water
Description: Patient/ Healthy volunteer will drink 5dl of Water
Study NCT00937092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: High-dose furosemide(HDF, furosemide 20 mg/h intravenously)
Study NCT00937092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low-dose dopamine + low-dose furosemide
Description: low-dose furosemide combined with low-dose dopamine (LDFD, furosemide 5 mg/h plus dopamine 5μg/kg/min intravenously)
Study NCT00628277 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high caloric expenditure exercise
Description: high caloric expenditure exercise plus dietary counseling
Study NCT00628277 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: low caloric expenditure exercise plus dietary counseling
Description: low caloric expenditure exercise plus dietary counseling
Study NCT02684123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apremilast
Description: Subjects will get drug or placebo
Study NCT02684123 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03060382 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: balanced buttress absorbable spacer
Description: For the patients of study group, a balanced buttress absorbable spacer was placed into the gap after the osteotomy of tibia and fibula to modify the lower limb line.
Study NCT03060382 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: total knee arthroplasty
Description: Total knee arthroplasty was conducted for the patients of control group
Study NCT04031196 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: QLB
Description: QLB type 2 approach
Study NCT04031196 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP block
Description: classic TAP block approach
Study NCT03257098 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allo-APZ2-CVU
Description: Suspension of ABCB5-positive mesenchymal stem cells
Study NCT03306979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N Acetylcysteine
Description: Patients will be randomized to receive N Acetylcysteine (NAC) (four 600 mg capsules given as 2 capsules in the morning and 2 capsules in the evening). The initial NAC dosage will be 600mg/day (one 600mg capsule in the morning) for the first week, followed by 1,200 mg/day (one 600 mg capsule in the morning, one 600mg capsule in the evening) for the second week, followed by 1,800 mg/day (two 600mg capsules in the morning, one 600mg capsule in the evening) for third week, followed by 2,400mg/day (two 600mg capsules in the morning, two 600mg capsules in the evening) for the following 21 weeks.
Study NCT03306979 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Patients will receive four placebo capsules (lactose-based filler) given as 2 capsules in the morning and 2 capsules in the evening, which will be prepared to mimic the weight of the experimental capsules.The initial placebo dosage will be 600mg/day (one 600mg capsule in the morning) for the first week, followed by 1,200 mg/day (one 600 mg capsule in the morning, one 600mg capsule in the evening) for the second week, followed by 1,800 mg/day (two 600mg capsules in the morning, one 600mg capsule in the evening) for third week, followed by 2,400mg/day (two 600mg capsules in the morning, two 600mg capsules in the evening) for the following 21 weeks.
Study NCT02121353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis
Description: Single-use 2 mL vial designed to deliver 0.05 mL of 10 mg/mL ranibizumab solution. Excipients: Alpha, alpha-trehalose dihydrate; histidine hydrochloride, monohydrate; histidine; polysorbate 20; water for injections Route of Administration: Intra-vitreal
Study NCT02121353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF582
Description: Single-use 2 mL vial designed to deliver 0.05 mL of 10 mg/mL ranibizumab solution. Excipients: Alpha, alpha-trehalose dihydrate; histidine hydrochloride, monohydrate; histidine; polysorbate 20; water for injections Route of Administration: Intra-vitreal
Study NCT00507065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mixed salts of a single-entity amphetamine (ADDERALL XR)
Study NCT03362034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: double transfer trays
Description: double trays one soft and one hard
Study NCT03362034 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: single transfer tray
Description: single soft tray
Study NCT01052363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab, CA4P
Study NCT00507065 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00638261 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: UVB-311nm
Description: UVB-311nm radiation given 3 times a week to one randomized body-half
Study NCT03027245 — intervention group
Intervention type: DRUG
Intervention: Eribulin
Study NCT03947593 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No intervention is being administered.
Study NCT04575584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molnupiravir
Description: Molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
Study NCT04575584 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
Study NCT03628716 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV301
Description: Prime with MVA-BN-CV301 (nominal titer 1.6 x 10\^9 Inf.U) given subcutaneously (SC) on Day 1 and Day 22. One dose = four 0.5 mL injections. One injection = nominal titer 4 x 10\^8 Inf.U in 0.5 mL.~Boost with FPV-CV301 (nominal titer of 1 × 10\^9 Inf.U in 0.5 mL, given SC every 21 days for 4 doses (on days 43, 64, 85, and 106), followed by boosts every 6 weeks until 6 months on trial (i.e., days 148 and 190), then every 12 weeks until completion of 2 years. One dose = one 0.5 mL injection.
Study NCT03628716 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab fixed dose of 1200 mg intravenous on Day 1 of each 21-day cycle
Study NCT01215435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Administered subcutaneously (under the skin) once daily, before breakfast. The trial has 3 treatment phases for both treatment arms
Study NCT01215435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Administered subcutaneously (under the skin) once daily, before dinner. The trial has 3 treatment phases for both treatment arms
Study NCT00511836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIVITROL 380 mg
Description: Administered via intramuscular (IM) injection once during the double-blind phase and for 2 additional injections, 4 weeks apart, during the optional open-label extension.
Study NCT00511836 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching VIVITROL 380 mg was administered by IM injection once during the double-blind phase, only.
Study NCT01943955 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: home-based computer gaming
Description: A computer mouse mounted to a headband and placed on the participant's head is used to interact with the game cursor. In order to interact with/play the game the participant must visually focus on the moving target and perform unpredictable head movements. Balance exercises are incorporated progressively and simultaneously during computer gaming.
Study NCT01603199 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High protein high fiber diet
Description: A personalized high protein high fiber dietary plan will be provided to each participant from both groups. Each participant will receive nutritional counseling once a month during six months.
Study NCT01693770 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRgFUS
Description: Focused ultrasound energy is accumulated into the target tissue (skeletal metastasis) thanks to the real time guidance of the MR images.
Study NCT00514982 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mesalamine
Description: 5-Aminosalicylic Acid Derivative used to treat mild to moderate Ulcerative Colitis
Study NCT00514982 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Infliximab
Description: Antirheumatic, Disease Modifying Gastrointestinal Agent, Miscellaneous, Monoclonal Antibody, Tumor Necrosis Factor (TNF) Blocking Agent used to treat gastrointestinal disorders.
Study NCT00514982 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Corticosteroids
Description: Systemic Corticosteroid used to treat inflammatory conditions.
Study NCT00514982 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 6-Mercaptopurine
Description: Antineoplastic Agent, Antimetabolite, Immunosuppressant Agent used traditionally to treat Acute lymphoblastic leukemia. Unlabeled use as steroid-sparing agent for corticosteroid-dependent Crohn's disease (CD) and ulcerative colitis (UC); maintenance of remission in CD; fistulizing Crohn's disease.
Study NCT00514982 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tacrolimus
Description: Immunosuppressant Agent used to treat Liver, Heart, Kidney transplant, prevent host vs graft disease, severe atopic dermatitis.
Study NCT00514982 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Adalimumab
Description: Antirheumatic, Monoclonal Antibody, Tumor Necrosis Factor (TNF) Blocking Agent used to treat Rheumatoid arthritis and Crohn's disease.
Study NCT00045734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given orally
Study NCT00045734 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00030823 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine
Study NCT00030823 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QS21
Study NCT00045734 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00636480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate
Description: Chlorhexidine gluconate (2% w/v) in an aqueous base, 26 ml applicator. Active drug contains alcohol and the placebo contains no drug. Administered topically.
Study NCT01130324 — intervention group
Intervention type: DRUG
Intervention: VIBATIV
Description: Observational
Study NCT00580749 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Naso jejunal feeding tube insertion
Description: Placement of feeding tube through nare and into jejunum for administration of enteral feeding.
Study NCT00580749 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NG feeding tube insertion
Description: Placement of naso gastric feeding tube into stomach for purpose of enteral feedings.
Study NCT02133833 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quantum Spectrum Radiation Emitter
Description: The patients receive stimulation treatment of Quantum Spectrum Radiation Emitter (5 quantum chips) daily for three weeks. The emitters are placed around the shoulder.
Study NCT02085070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: IV MK-3475
Study NCT02085070 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MK-3475
Description: IV MK-3475
Study NCT03331705 — intervention group
Intervention type: DEVICE
Intervention: Uro-C (Use of new cystoscope)
Description: Diagnostic cystoscopic procedure of the urethra and bladder
Study NCT02157597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NIRS based management
Description: 1. Check NIRS, mechanics, muscle relaxation, hemodynamics, ventilation, hematocrit, surgical repair~2. Deepen anesthesia with volatile or intravenous agent.~3. Consider Extra-Corporeal Membrane Oxygenation (ECMO).
Study NCT02157597 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: During the Control Arm, the medical team completes all tasks as clinically necessary and in the best medical interest of the patient, without any input from the study procedures
Study NCT03063099 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ReNu™ Injection
Description: Injection into the hip for the treatment of Osteoarthritis.
Study NCT02481180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T0001
Description: injection (SC) T0001 15mg weekly for 12 weeks
Study NCT02481180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T0001
Description: injection (SC) T0001 30mg weekly for 12 weeks
Study NCT02481180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T0001
Description: injection (SC) T0001 30mg every two weeks for 12 weeks
Study NCT02481180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T0001
Description: injection (SC) T0001 50mg every two weeks for 12 weeks
Study NCT02481180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enbrel
Description: injection (SC) enbrel 50mg twice a week for 12 weeks
Study NCT04511000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipilou®(generic atorvastatin drug) 20 mg
Description: Patients assigned to experimental group are treated with Lipilou® 20 mg
Study NCT04511000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipilou®(generic atorvastatin drug) 10 mg
Description: Patients assigned to comparator group are treated with Lipilou® 10 mg
Study NCT00636480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ChloraPrep One Step
Description: Administer topically
Study NCT00636480 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile saline
Description: 0.9% NaCl solution
Study NCT01488955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 400 mg oral once a day from day 0 for 3 days
Study NCT01488955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin-Trometamol
Description: 8 g granulate with 3 g Fosfomycin-Trometamol oral once at day 0, placebo to Ibuprofen once a day oral from day 0 for 3 days
Study NCT04553445 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronotype
Description: Participants screened using the Morningness/Eveningness Questionnaire. Chronotype categorized as either Definite Morning/Morning, or Evening/Definite Evening. Participant will exercise (60-70% estimated heart rate max, 2 x per week, 30-min/session) either in sync or not in sync with chronotype for one month in a randomized cross-over design. There will be a one-month wash out period, and then participant will complete training in the alternate chronotype for one month.
Study NCT04553445 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Green exercise
Description: Participants will be randomly assigned to four weeks of moderate intensity aerobic exercise (60-70% estimated heart rate max, 2 x per week, 30-min/session) in either natural or indoor environments in a randomized cross-over design. There will be a one-month wash out period, and then participant will complete training in alternate environment for one month.
Study NCT01906983 — intervention group
Intervention type: OTHER
Intervention: Doppler Ultrasound
Description: Doppler ultrasound will be performed to patients with blunt splenic trauma, prior to discharge and again, at 3-6 months in patients with thrombosis indication.
Study NCT01389414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab plus GEMOX chemotherapy
Description: panitumumab 6 mg/kg will be administered over 60 minute +/- 15 minutes on day 1 followed by Gemcitabine 1000mg/sqm administered by intravenous infusion as 1-hour infusion on day 1 of each cycle. Oxaliplatin 100mg/sqm will be administered by intravenous infusion as 2-hour infusion on day 2 of each cycle.
Study NCT01389414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEMOX chemotherapy
Description: Gemcitabine 1000mg/sqm will be administered by intravenous infusion as 1-hour infusion on day 1 of each cycle. Oxaliplatin 100mg/sqm will be administered by intravenous infusion as 2-hour infusion on day 2 of each cycle.
Study NCT01389414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GEMOX chemotherapy
Description: Gemcitabine 1000mg/sqm will be administered by intravenous infusion as 1-hour infusion on day 1 of each cycle. Oxaliplatin 100mg/sqm will be administered by intravenous infusion as 2-hour infusion on day 2 of each cycle.
Study NCT03163043 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino Acid Intake
Description: Amino acid intakes will be varied at 0.2-2.67 g/kg/d
Study NCT02731911 — intervention group
Intervention type: DRUG
Intervention: dexamethasone intravitreal implant
Description: Ozurdex® treatment for diabetic macular oedema as per standard of care in clinical practice.
Study NCT03669198 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: NT-Pro BNP
Description: . AHF patients who met inclusion and exclusion criteria were randomly assigned to 2 groups, NT-pro BNP group and control group. In the NT-pro BNP group, serial NT-pro BNP levels at admission and pre-discharge was measured, the latter with the target of decrease ≥ 30% NT-pro BNP level. Randomised patients were followed during treatment up to 90 days post-discharge to assess short-term outcomes and costs.
Study NCT01278706 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endometrial biopsy/ies
Description: performing office endometrial biopsy with a disposable sterile catheter
Study NCT02994784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propylene Glycol-Free Melphalan Hydrochloride
Description: Intravenous Propylene Glycol-Free Melphalan Hydrochloride
Study NCT02383992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3% H2O2 solution
Study NCT02383992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% normal saline
Study NCT02484378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CER-001
Description: Engineered pre-beta HDL particle
Study NCT02484378 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study NCT04120376 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contraception Counseling
Description: Each participant will receive a 10 minute confidential contraception counseling session with an APP in the Emergency Department
Study NCT04950036 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Test
Description: The results of hip arthroscopy were taken as the gold standard and MRI examination was taken as the research object.